European Myeloma Network B.v.

This study tests whether adding the drug teclistamab to standard maintenance therapy (lenalidomide) can better prevent multiple myeloma from returning after a stem cell transplant. About 1,600 adults with newly diagnosed myeloma who have already responded to initial treatment wil…

This study tests a drug called teclistamab in 30 people with AL amyloidosis, a rare disease where abnormal proteins damage organs. Participants have already had other treatments that didn't work well enough. The goal is to see if teclistamab can improve blood markers of the disea…

This study tests two different drug combinations (teclistamab plus daratumumab or talquetamab plus daratumumab) given for a fixed time in 150 frail patients newly diagnosed with multiple myeloma. The goal is to see how long the cancer stays under control and how well patients tol…

This study tests whether adding the experimental drug linvoseltamab after standard initial therapy works better than continuing standard therapy alone for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 1,000 participants will be randoml…

This study collects blood and tissue samples from 6,000 people with multiple myeloma, smoldering myeloma, plasma cell leukemia, or MGUS. Researchers will store these samples in a biobank to study the diseases and improve future care. Participants do not receive any treatment as p…